newsfilter
← Latest News
GlobeNewswire·

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of